Indomethacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Indomethacin: From Inflammatory Arthritis to Brachydactyly-Syndactyly Syndrome
One-Sentence Summary
Indomethacin is an NSAID used mainly for inflammatory joint conditions such as rheumatoid arthritis, ankylosing spondylitis, gout and osteoarthritis. It is also used to close a patent ductus arteriosus. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, a rare congenital limb malformation. This prediction currently has 0 clinical trials and 0 publications supporting it, so it is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Inflammatory arthritis and related conditions (e.g., rheumatoid arthritis, ankylosing spondylitis, gout, osteoarthritis, bursitis, tendinitis, patent ductus arteriosus). The Singapore registration records do not state an indication, so this is based on the knowledge graph. |
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Indomethacin is a non-selective COX-1/COX-2 inhibitor. It reduces prostaglandin-driven inflammation, pain and fever, which explains its efficacy in arthritis and gout.
The predicted condition is a congenital limb malformation. It is a developmental disorder, not an inflammatory one, so no plausible link to COX inhibition is evident in the data provided. The very high score most likely reflects the model's network proximity to indomethacin's many skeletal and joint indications, not a true biological relationship. A high score alone should not be read as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05375P | INDO CAPSULES 25 mg | Capsule | Not stated in registration data |
| SIN08624P | INDOMEN CAPSULE 25 mg | Capsule | Not stated in registration data |
| SIN09699P | HD-METHACIN CAPSULE 25 mg | Capsule | Not stated in registration data |
All three are valid single-ingredient oral products, and none has been cancelled.
Safety Considerations
- Contraindication-related conditions (from a biomedical knowledge graph, not label text):
- Cardiovascular: hypertension, myocardial infarction, coronary thrombosis, heart disease
- Gastrointestinal: gastric ulcer, duodenal ulcer, active peptic ulcer disease, ulcerative colitis, inflammatory bowel disease, necrotizing enterocolitis
- Renal and hepatic: kidney disease, liver disease, gallbladder disease
- Haematological: thrombocytopenia, blood coagulation disease, hemoglobinopathy
- Respiratory: asthma (including intrinsic and allergic asthma)
- Neurological and psychiatric: epilepsy, intracerebral haemorrhage, anxiety disorder, neurotic disorder, dysthymic disorder
- Other: infectious disease, pyoureter, oesophageal dyskinesia
- Drug Interactions: 100 interactions were recorded in total. Those reviewed were mostly Moderate, with some Minor.
- Moderate: aspirin, corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), metformin, glimepiride, chlorpropamide, aprepitant, mesalazine, balsalazide, and potassium salts
- Minor: H2 blockers (famotidine, ranitidine, cimetidine) and linaclotide
For full warnings and contraindications, please refer to the package insert, which was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone, with no trials, no literature and no plausible mechanism linking COX inhibition to a congenital limb malformation. Indomethacin also carries significant GI, renal and cardiovascular risks that would need a clear benefit to justify.
To proceed, the following is needed:
- Evidence of a biological mechanism connecting prostaglandin synthesis inhibition to this syndrome's pathology
- Any clinical or preclinical studies in this condition
- Mechanism of action data and the HSA package insert warnings and contraindications
- Approved indication text for the Singapore registrations
Note on other candidates: Among the other predictions for indomethacin, juvenile idiopathic arthritis (L3) has the most supporting literature. This includes a 1978 double-blind crossover study (ketoprofen vs. indomethacin) and several pediatric NSAID reviews. It is a close extension of existing arthritis use, but the evidence is dated and symptomatic only. This would be a more sensible direction to evaluate than the brachydactyly-syndactyly prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.